Use of a Chagas Urine Nanoparticle Test (Chunap) to Correlate with Parasitemia Levels in T. cruzi/HIV Co-infected Patients

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Castro-Sesquen, Yagahira E.
    • Other Affiliation: Laboratorio de Investigación en Enfermedades Infecciosas; Universidad Peruana Cayetano Heredia
  • Gilman, Robert H.
    • Other Affiliation: Department of International Health; Bloomberg School of Hygiene and Public Health; Johns Hopkins University
  • Mejia, Carolina
  • Clark, Daniel E.
    • Other Affiliation: Department of Internal Medicine and Pediatrics; Vanderbilt University
  • Choi, Jeong
    • Other Affiliation: Division of Cardiovascular Medicine; University of California Davis
  • Reimer-McAtee, Melissa J.
    • Other Affiliation: Tulane University Medical Center
  • Castro, Rosario
    • Other Affiliation: Servicio de Infectología; Hospital Clínico Viedma
  • Valencia-Ayala, Edward
    • Other Affiliation: Laboratorio de Investigación en Enfermedades Infecciosas; Universidad Peruana Cayetano Heredia
  • Flores, Jorge
    • Other Affiliation: Hospital San Juan De Dios
  • Bowman, Natalie
    • Affiliation: School of Medicine, Department of Medicine
  • Castillo-Neyra, Ricardo
    • Other Affiliation: Perelman School of Medicine; University of Pennsylvania
  • Torrico, Faustino
    • Other Affiliation: Universidad Mayor de San Simón
  • Liotta, Lance
    • Other Affiliation: Center for Applied Proteomics and Molecular Medicine; George Mason University
  • Bern, Caryn
    • Other Affiliation: Global Health Sciences; Department of Epidemiology and Biostatistics; School of Medicine; University of California; San Francisco
  • Luchini, Alessandra
    • Other Affiliation: Center for Applied Proteomics and Molecular Medicine; George Mason University
Abstract
  • BackgroundEarly diagnosis of reactivated Chagas disease in HIV patients could be lifesaving. In Latin America, the diagnosis is made by microscopical detection of the T. cruzi parasite in the blood; a diagnostic test that lacks sensitivity. This study evaluates if levels of T. cruzi antigens in urine, determined by Chunap (Chagas urine nanoparticle test), are correlated with parasitemia levels in T. cruzi/HIV co-infected patients.Methodology/Principal FindingsT. cruzi antigens in urine of HIV patients (N = 55: 31 T. cruzi infected and 24 T. cruzi serology negative) were concentrated using hydrogel particles and quantified by Western Blot and a calibration curve. Reactivation of Chagas disease was defined by the observation of parasites in blood by microscopy. Parasitemia levels in patients with serology positive for Chagas disease were classified as follows: High parasitemia or reactivation of Chagas disease (detectable parasitemia by microscopy), moderate parasitemia (undetectable by microscopy but detectable by qPCR), and negative parasitemia (undetectable by microscopy and qPCR). The percentage of positive results detected by Chunap was: 100% (7/7) in cases of reactivation, 91.7% (11/12) in cases of moderate parasitemia, and 41.7% (5/12) in cases of negative parasitemia. Chunap specificity was found to be 91.7%. Linear regression analysis demonstrated a direct relationship between parasitemia levels and urine T. cruzi antigen concentrations (p<0.001). A cut-off of > 105 pg was chosen to determine patients with reactivation of Chagas disease (7/7). Antigenuria levels were 36.08 times (95% CI: 7.28 to 64.88) higher in patients with CD4+ lymphocyte counts below 200/mL (p = 0.016). No significant differences were found in HIV loads and CD8+ lymphocyte counts.ConclusionChunap shows potential for early detection of Chagas reactivation. With appropriate adaptation, this diagnostic test can be used to monitor Chagas disease status in T. cruzi/HIV co-infected patients.Author SummaryReactivation of Chagas disease in people living with HIV is a serious clinical condition that is associated with high mortality. Hence, early diagnosis and treatment can be lifesaving. Although there are not well accepted criteria to identify patients at risk of reactivation, parasitemia levels are usually considered as the best predictor. Microscopy is used in Latin America for detection of parasitemia levels. However, this has low sensitivity, which usually leads to a delay in diagnosis and treatment. Quantitative PCR is used only for research proposes in endemic areas. Antigens in urine (antigenuria) are correlated with parasitemia levels in animal models, as well as in cases of congenital Chagas disease. We believe that antigenuria can also be used for prediction of parasitemia levels in T. cruzi/HIV co-infected patients. In this study, Chunap (Chagas urine nanoparticle test) was used for concentration and quantification of T. cruzi antigens in urine of T. cruzi/HIV co-infected patients. Values of more than 105 pg of T. cruzi antigens in urine were observed only in patients with reactivation of Chagas disease. This study shows that antigenuria levels are highly correlated to levels of parasitemia and can be used as a non-invasive technique for monitoring parasitemia levels in T. cruzi/HIV co-infected patients.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • PLoS Neglected Tropical Diseases
Journal volume
  • 10
Journal issue
  • 2
Page start
  • e0004407
Language
  • English
ISSN
  • 1935-2727
  • 1935-2735

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details PubMedCentral-PMC4768913.pdf 2016 Public Download